BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren’s contracture and Peyronie’s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.

WILMINGTON, Del., Dec. 2, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today...

BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals

New York, New York--(Newsfile Corp. - November 13, 2020) - Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether BioSpecifics Technologies Corp. (NASDAQ: BSTC) agreement to be acquired by Endo International PLC is fair to shareholders.Under the terms of the agreement, a tender offer expiring on December 2nd was commenced by Endo International to acquire BioSpecifics Technologies for $88.50...

Moore Kuehn Encourages BSTC Investors to Contact Law Firm

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC investor,...

Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., CONSOL Energy Inc., CONSOL Coal Resources LP, Endurance International Group Holdings, Inc., GCI Liberty, Inc., Liberty Broa

BioSpecifics (BSTC) delivered earnings and revenue surprises of 315.79% and 106.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

BioSpecifics Technologies (BSTC) Surpasses Q3 Earnings and Revenue Estimates

WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as...

BioSpecifics Reports Third Quarter 2020 Financial and Operating Results

WILMINGTON, Del., Nov. 6, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. ("BioSpecifics") (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics' agreement to be...

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: BioSpecifics Technologies (BSTC) Q3 Earnings Expected to Decline

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. ("BSTC" or the "Company") (NASDAQ: BSTC) in connection with the proposed acquisition of the...

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the pr

BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company")...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioSpecifics Technologies Corp. - BSTC

NEW YORK, Oct. 27, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC investor,...

Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., CONSOL Energy Inc., CONSOL Coal Resources LP, GCI Liberty, Inc., Liberty Broadband Corporation, Parsley Energy, Inc., Pione

Endo International

New York, New York--(Newsfile Corp. - October 21, 2020) - [DATELINE]Rowley Law PLLC is investigating potential securities law violations by BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors concerning the proposed acquisition of the company by Endo International plc (NASDAQ: ENDP). Stockholders will receive $88.50 for each share of BioSpecifics Technologies stock that they hold. The transaction is valued at approximately $658 million and is expected to close in the fourth quarter of...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioSpecifics Technologies Corp.

Investors are fired up about Endo's planned acquisition of BioSpecifics.

Why Endo International and BioSpecifics Technologies Stocks Soared Today

New York, New York--(Newsfile Corp. - October 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company") stock prior to October 19, 2020.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of BioSpecifics Technologies Corp. to Endo International Plc

News that Endo International PLC (NASDAQ: ENDP) would acquire BioSpecifics Technologies Corp.

Are BioSpecifics Shareholders Getting Enough in the Endo Buyout?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioSpecifics Technologies Corp. (NASDAQ: BSTC) to Endo International plc for $88.50 per share is fair to BioSpecifics shareholders. On behalf of BioSpecifics shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are a BioSpecifics shareholde

BioSpecifics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioSpecifics Technologies Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BSTC

-- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage...

Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™

WILMINGTON, Del., Oct. 19, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated equity value of approximately...

BioSpecifics to be Acquired by Endo Pharmaceuticals

WILMINGTON, Del., Sept. 14, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.

BioSpecifics to Present at the Virtual Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit

WILMINGTON, Del., Sept. 8, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.

BioSpecifics to Present at the H.C. Wainwright Virtual Healthcare Conference

BioSpecifics (BSTC) delivered earnings and revenue surprises of 320.00% and 89.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BioSpecifics Technologies (BSTC) Surpasses Q2 Earnings and Revenue Estimates

Shares of BioSpecifics Technologies (NASDAQ:BSTC) rose 2% in pre-market trading after the company reported Q2 results.

Recap: BioSpecifics Technologies Q2 Earnings

Analysts Estimate BioSpecifics Technologies (BSTC) to Report a Decline in Earnings: What to Look Out for

WILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.

BioSpecifics Appoints Alex Monteith as Chief Business Officer

BioSpecifics Technologies Could Surge If The FDA Approves Its 'CCH' In XiaFlex To Treat Cellulite In The Buttocks

News for BioSpecifics Technologies Stock (BSTC)